<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To unravel crucial <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (VWF) interactions that are detrimental in <z:hpo ids='HP_0001297'>stroke</z:hpo> development </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: VWF(-/-) mice received gene transfer to express mutants of VWF defective either in binding to fibrillar collagen, <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (GP)Ibα or GPIIb/IIIa, and underwent 60 minutes of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In VWF(-/-) mice reconstituted with VWF mutants defective in binding to collagen or GPIbα, protection against <z:hpo ids='HP_0001297'>stroke</z:hpo> was sustained, whereas VWF lacking the GPIIb/IIIa binding site restored full susceptibility similar to <z:mpath ids='MPATH_458'>normal</z:mpath> VWF </plain></SENT>
<SENT sid="3" pm="."><plain>CONCLUSIONS: VWF-collagen and VWF-GPIbα (but not VWF-GPIIb/IIIa) interactions are instrumental in <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation after transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, and their inhibition could be a promising target for <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment </plain></SENT>
</text></document>